Daewon Pharmaceutical Co., Ltd.
PharmaSeoul, South Korea, South Korea · Est. 1974
Daewon Pharmaceutical is a South Korean pharmaceutical company that develops and manufactures prescription and over-the-counter drugs across multiple therapeutic areas.
0
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
0
Indications↗
Distinct diseases across all programs
47
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Key Events
Mar 6, 2026TrialA Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunteers
Feb 1, 2026TrialDrug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin
Feb 1, 2026TrialEvaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers
Dec 28, 2025TrialA Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult Volunteers
Dec 1, 2025TrialA Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs
May 8, 2025TrialClinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers
Apr 21, 2025TrialClinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A
Nov 21, 2024TrialStudy to Evaluate the Effect of Food on the Pharmacokinetics and Pharmacodynamics Characteristics in Healthy Adult Volunteers
3 more events
Sep 9, 2024TrialStudy to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma
Mar 28, 2024TrialA Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212
Oct 27, 2022TrialClinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
oncologycardiovasculargastroenterologydermatology
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)